Literature DB >> 32107180

Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.

Ambika P Ashraf1, Kazuya Miyashita2, Katsuyuki Nakajima3, Masami Murakami3, Robert A Hegele4, Michael Ploug5, Loren G Fong6, Stephen G Young7, Anne P Beigneux8.   

Abstract

Chylomicronemia caused by a deficiency in lipoprotein lipase (LPL) or GPIHBP1 (the endothelial cell protein that transports LPL to the capillary lumen) is typically diagnosed during childhood and represents a serious, lifelong medical problem. Affected patients have high plasma triglyceride levels (>1500 mg/dL) and a high risk of acute pancreatitis. However, chylomicronemia frequently presents later in life in the absence of an obvious monogenic cause. In these cases, the etiology for the chylomicronemia is presumed to be "multifactorial" (involving diabetes, drugs, alcohol, or polygenic factors), but on a practical level, the underlying cause generally remains a mystery. Here, we describe a 15-year-old female with chylomicronemia caused by GPIHBP1 autoantibodies (which abolish LPL transport to the capillary lumen). Remarkably, chylomicronemia in this patient was intermittent, interspersed between periods when the plasma triglyceride levels were normal. GPIHBP1 autoantibodies were easily detectable during episodes of chylomicronemia but were undetectable during periods of normotriglyceridemia. During the episodes of chylomicronemia (when GPIHBP1 autoantibodies were present), plasma LPL levels were low, consistent with impaired LPL transport into capillaries. During periods of normotriglyceridemia, when GPIHBP1 autoantibodies were absent, plasma LPL levels normalized. Because the chylomicronemia in this patient was accompanied by debilitating episodes of acute pancreatitis, the patient was ultimately treated with immunosuppressive drugs, which resulted in disappearance of GPIHBP1 autoantibodies and normalization of plasma triglyceride levels. GPIHBP1 autoantibodies need to be considered in patients who present with unexplained acquired cases of chylomicronemia.
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GPIHBP1; LPL; lipoprotein lipase

Mesh:

Substances:

Year:  2020        PMID: 32107180      PMCID: PMC7166156          DOI: 10.1016/j.jacl.2020.01.012

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  16 in total

1.  Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Authors:  Anne P Beigneux; Kazuya Miyashita; Michael Ploug; Dirk J Blom; Masumi Ai; MacRae F Linton; Weerapan Khovidhunkit; Robert Dufour; Abhimanyu Garg; Maureen A McMahon; Clive R Pullinger; Norma P Sandoval; Xuchen Hu; Christopher M Allan; Mikael Larsson; Tetsuo Machida; Masami Murakami; Karen Reue; Peter Tontonoz; Ira J Goldberg; Philippe Moulin; Sybil Charrière; Loren G Fong; Katsuyuki Nakajima; Stephen G Young
Journal:  N Engl J Med       Date:  2017-04-05       Impact factor: 91.245

2.  GPIHBP1 C89F neomutation and hydrophobic C-terminal domain G175R mutation in two pedigrees with severe hyperchylomicronemia.

Authors:  Sybil Charrière; Noël Peretti; Sophie Bernard; Mathilde Di Filippo; Agnès Sassolas; Micheline Merlin; Mireille Delay; Cyrille Debard; Etienne Lefai; Alain Lachaux; Philippe Moulin; Christophe Marçais
Journal:  J Clin Endocrinol Metab       Date:  2011-08-03       Impact factor: 5.958

Review 3.  The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.

Authors:  Alan Chait; Robert H Eckel
Journal:  Ann Intern Med       Date:  2019-04-30       Impact factor: 25.391

Review 4.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis.

Authors:  Stephen G Young; Rudolf Zechner
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

Review 5.  GPIHBP1 and Plasma Triglyceride Metabolism.

Authors:  Loren G Fong; Stephen G Young; Anne P Beigneux; André Bensadoun; Monika Oberer; Haibo Jiang; Michael Ploug
Journal:  Trends Endocrinol Metab       Date:  2016-05-14       Impact factor: 12.015

6.  Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.

Authors:  John MacIsaac; Reda Siddiqui; Erin Jamula; Na Li; Steven Baker; Kathryn E Webert; Denise Evanovitch; Nancy M Heddle; Donald M Arnold
Journal:  Transfusion       Date:  2018-09-23       Impact factor: 3.157

7.  The evolving clinical course of patients with insulin receptor autoantibodies: spontaneous remission or receptor proliferation with hypoglycemia.

Authors:  J S Flier; R S Bar; M Muggeo; C R Kahn; J Roth; P Gorden
Journal:  J Clin Endocrinol Metab       Date:  1978-11       Impact factor: 5.958

8.  Deletion of GPIHBP1 causing severe chylomicronemia.

Authors:  Jonathan J Rios; Savitha Shastry; Juan Jasso; Natalie Hauser; Abhimanyu Garg; André Bensadoun; Jonathan C Cohen; Helen H Hobbs
Journal:  J Inherit Metab Dis       Date:  2011-10-19       Impact factor: 4.982

9.  LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias.

Authors:  Christopher T Johansen; Joseph B Dubé; Melissa N Loyzer; Austin MacDonald; David E Carter; Adam D McIntyre; Henian Cao; Jian Wang; John F Robinson; Robert A Hegele
Journal:  J Lipid Res       Date:  2014-02-06       Impact factor: 5.922

10.  Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.

Authors:  Lauren C Bylsma; Jon P Fryzek; Karynsa Cetin; Fiona Callaghan; Carla Bezold; Bhakti Mehta; Jeffrey S Wasser
Journal:  Am J Hematol       Date:  2018-10-21       Impact factor: 10.047

View more
  4 in total

Review 1.  Chylomicronemia from GPIHBP1 autoantibodies.

Authors:  Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2020-09-18       Impact factor: 5.922

2.  A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism.

Authors:  Stephen G Young; Wenxin Song; Ye Yang; Gabriel Birrane; Haibo Jiang; Anne P Beigneux; Michael Ploug; Loren G Fong
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

3.  Case Studies in Pediatric Lipid Disorders and Their Management.

Authors:  Ambika P Ashraf; Bhuvana Sunil; Vaneeta Bamba; Emily Breidbart; Preneet Cheema Brar; Stephanie Chung; Anshu Gupta; Aditi Khokhar; Seema Kumar; Marissa Lightbourne; Manmohan K Kamboj; Ryan S Miller; Nivedita Patni; Vandana Raman; Amy S Shah; Don P Wilson; Brenda Kohn
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

Review 4.  GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity.

Authors:  Kristian Kølby Kristensen; Katrine Zinck Leth-Espensen; Anni Kumari; Anne Louise Grønnemose; Anne-Marie Lund-Winther; Stephen G Young; Michael Ploug
Journal:  Front Cell Dev Biol       Date:  2021-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.